The financing includes €8.5 million in equity led by Point72 Ventures from the U.S. and Vsquared Ventures from Munich.

Berlin-based startup Quantune Technologies has successfully raised €13.5 million in a seed financing round, announced today, to advance its innovative health monitoring technology.

However, the company faces challenges in stabilizing its technology for real-world use, particularly during physical activity, where accurate measurements are difficult.

The pursuit of non-invasive glucose monitoring continues to attract significant interest, with numerous startups and major companies like Apple exploring solutions.

While the FDA has approved several continuous glucose monitoring devices, such as the FreeStyle Libre, these still require a small sensor to be inserted under the skin.

In addition to this recent funding, Quantune has previously secured over €5 million in public grants from the European Innovation Council and the Investment Bank of Berlin.

Co-Founder Jan F. Kischkat emphasized that this funding will significantly aid in research, development, and productization efforts.

The funds will be utilized to enhance detection capabilities, optimize the spectrometer's design, and meet regulatory standards for global market entry.

Founded in 2019, Quantune develops a miniaturized infrared laser spectrometer designed for continuous, non-invasive health monitoring.

Their wrist-worn device utilizes a patented Quantum-Cascade Laser spectrometer to measure biomarkers like glucose and lactate with lab-quality precision.

Michael Jobst from Vsquared Ventures praised Quantune's technology for its precision and potential to revolutionize healthcare for both chronically ill patients and health-conscious individuals.

Quantune plans to use part of the investment to hire talent across various departments to support its growth.